Literature DB >> 8609402

Regulation of 3' IgH enhancers by a common set of factors, including kappa B-binding proteins.

J S Michaelson1, M Singh, C M Snapper, W C Sha, D Baltimore, B K Birshtein.   

Abstract

Targeted disruption of the p50 subunit of NF-kappa B resulted in isotype class switch defects resembling those observed in mice in which the downstream IgH enhancer 3'alpha E(hs1,2) was deleted. We postulated that kappa B binding proteins may regulate class switching by interacting with 3'alpha E(hs1,2) or with other IgH 3' enhancers with which 3'alpha E(hs1,2) synergizes. kappa B binding sites were identified in 3'alpha E(hs1,2) and 3' alpha-hs4, the distal 3' IgH enhancer. A kappa B binding site within 3'alpha E(hs1,2) contributes to at least half the activity of the enhancer in plasma cells, while the same kappa B binding site participates in the complex repression of the enhancer in B cells. In the case of 3'alpha-hs4, a kappa B binding complex activates the enhancer in pre-B, B cells and plasma cells. Additional binding sites within 3'alpha-hs4 for factors known to regulate 3'alpha E(hs1,2), including Oct-1 and BSAP, were identified, and their contribution to 3'alpha-hs4 regulation during B cell development was assessed. Oct-1 positively regulates the enhancer in pre-B and B cells, while BSAP is a repressor in pre-B cells and an activator at the B cell stage. These studies identify kappa B binding proteins as key modulators of 3'alpha E(hs1,2) and 3'alpha-hs4, and suggest coregulation of the two enhancers by a common set of factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609402

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  BSAP can repress enhancer activity by targeting PU.1 function.

Authors:  S Maitra; M Atchison
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  Transcriptional activation by LR1 at the Emu enhancer and switch region sites.

Authors:  L A Hanakahi; N Maizels
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

Review 3.  NF-kappaB pathways in the immune system: control of the germinal center reaction.

Authors:  Christine A Goetz; Albert S Baldwin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Interaction between the immunoglobulin heavy chain 3' regulatory region and the IgH transcription unit during B cell differentiation.

Authors:  Zhongliang Ju; Sanjukta Chatterjee; Barbara K Birshtein
Journal:  Mol Immunol       Date:  2011-09-25       Impact factor: 4.407

5.  The aryl hydrocarbon receptor regulates an essential transcriptional element in the immunoglobulin heavy chain gene.

Authors:  Michael J Wourms; Courtney E W Sulentic
Journal:  Cell Immunol       Date:  2015-02-26       Impact factor: 4.868

6.  The AhR and NF-κB/Rel Proteins Mediate the Inhibitory Effect of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin on the 3' Immunoglobulin Heavy Chain Regulatory Region.

Authors:  Richard L Salisbury; Courtney E W Sulentic
Journal:  Toxicol Sci       Date:  2015-09-16       Impact factor: 4.849

7.  Dynamic changes in binding of immunoglobulin heavy chain 3' regulatory region to protein factors during class switching.

Authors:  Sanjukta Chatterjee; Zhongliang Ju; Rabih Hassan; Sabrina A Volpi; Alexander V Emelyanov; Barbara K Birshtein
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

8.  Requirement for NF-kappaB in osteoclast and B-cell development.

Authors:  G Franzoso; L Carlson; L Xing; L Poljak; E W Shores; K D Brown; A Leonardi; T Tran; B F Boyce; U Siebenlist
Journal:  Genes Dev       Date:  1997-12-15       Impact factor: 11.361

9.  Discovery platform for inhibitors of IgH gene enhancer activity.

Authors:  Nathan G Dolloff
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

10.  Diverse chemicals including aryl hydrocarbon receptor ligands modulate transcriptional activity of the 3'immunoglobulin heavy chain regulatory region.

Authors:  Rebecca A Henseler; Eric J Romer; Courtney E W Sulentic
Journal:  Toxicology       Date:  2009-03-31       Impact factor: 4.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.